Please login to the form below

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab. New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift'
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

The latest news from the FDA continues to back this belief and puts MK-3475 on course to be the first anti-PD-1 antibody approved in the US. . ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). MK-3475 was

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

The science of the deal: Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis: For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy: Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...